Although molecular markers for osteosarcoma diagnosis are still lacking, some genetic studies have demonstrated that mutations in tumor suppressor genes (TSGs), such as P53, Rb, and c-Myc, in osteosarcoma may be related to therapy efficiency and prognosis [4,5,6,7,8,9,10]. This evidence concerns the gene RB1 and osteosarcoma.